Bank of New York Mellon Corp bought a new position in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 234,896 shares of the company's stock, valued at approximately $10,902,000. Bank of New York Mellon Corp owned 0.42% of Astrana Health as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently bought and sold shares of ASTH. Strs Ohio acquired a new position in shares of Astrana Health during the 4th quarter valued at about $40,000. Tower Research Capital LLC TRC boosted its holdings in shares of Astrana Health by 323.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company's stock valued at $115,000 after purchasing an additional 3,517 shares during the last quarter. State of Wyoming acquired a new stake in Astrana Health during the second quarter worth about $132,000. Los Angeles Capital Management LLC acquired a new stake in Astrana Health during the 4th quarter worth approximately $228,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Astrana Health in the 2nd quarter valued at $233,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on ASTH shares. Needham & Company LLC upped their target price on shares of Astrana Health from $30.00 to $41.00 and gave the company a "buy" rating in a research note on Friday, May 8th. Truist Financial boosted their price objective on shares of Astrana Health from $47.00 to $55.00 and gave the stock a "buy" rating in a report on Monday, August 10th. TD Cowen upped their price objective on shares of Astrana Health from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Tuesday, July 14th. BTIG Research raised their target price on Astrana Health from $50.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Finally, Barclays lifted their target price on Astrana Health from $50.00 to $53.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $49.43.
Check Out Our Latest Research Report on ASTH
Astrana Health Stock Performance
Shares of ASTH opened at $38.57 on Thursday. The firm has a fifty day moving average of $41.19 and a 200-day moving average of $34.49. The company has a market cap of $2.15 billion, a price-to-earnings ratio of 47.04 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.23 and a current ratio of 1.23. Astrana Health, Inc. has a 1 year low of $18.08 and a 1 year high of $51.60.
Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.46. Astrana Health had a net margin of 1.05% and a return on equity of 10.30%. The company had revenue of $972.52 million during the quarter, compared to analyst estimates of $985.62 million. During the same period in the prior year, the business posted $0.19 EPS. The business's revenue for the quarter was up 48.5% compared to the same quarter last year. As a group, equities analysts anticipate that Astrana Health, Inc. will post 1.32 earnings per share for the current year.
About Astrana Health
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.
Featured Articles
Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. (NASDAQ:ASTH - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
